Astellas antifungal gets EU nod
The EMA’s Committee for Medicinal Products for Human Use (CHMP) has recommended Basilea’s Cresemba – which is marketed by Astellas in the US – for the treatment of rare fungal infections.
Read MoreAuthor: George Underwood
MHRA confirms safety of Boehringer stroke drug
The MHRA has reconfirmed that the benefits of Boehringer Ingelheim’s controversial stroke drug Actilyse outweigh its risks in a new review.
Read MoreMotif novel antibiotic gets FDA recognition
The FDA has designated Motif Bio’s novel antibiotic iclaprim as a Qualified Infectious Diseases Product (QIDP).
Read MoreCall for NHS transformation fund
The Health Foundation and the King’s Fund have called for a dedicated ‘Transformation Fund’ to help deliver change for the NHS.
Read MoreNovavax Ebola vaccine impresses in early trial
Novavax’s Ebola vaccine has been shown to be highly effective in a Phase I trial.
Read More- Enterprise reports positive phase 2 data for inhaled ENaC blocker in cystic fibrosis
- SMC backs first-line metastatic bladder cancer combination after trial results
- Poolbeg secures Canadian patent for POLB 001 in cancer immunotherapy‑induced CRS
- Pulsesight reports positive phase 1 data for PST‑611 in dry AMD
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
